Biomedical Engineering Reference
In-Depth Information
108. Portera, C.C.,
, Cardiac toxicity and efficacy of trastuzumab
combined with pertuzumab in patients with [corrected] human
epidermal growth factor receptor 2-positive metastatic breast cancer.
Clin Cancer Res
et al.
, 2008.
14
(9): 2710-6.
109. Gianni, L.,
, Open-label, phase II, multicenter, randomized study
of the efficacy and safety of two dose levels of Pertuzumab, a human
epidermal growth factor receptor 2 dimerization inhibitor, in patients
with human epidermal growth factor receptor 2-negative metastatic
breast cancer.
et al.
J Clin Oncol
, 2010.
28
(7): 1131-1137.
110. Muss, H.B.,
, c-erbB-2 expression and response to adjuvant therapy
in women with node-positive early breast cancer.
et al.
N Engl J Med
, 1994.
(18): 1260-1266.
111. Paik, S.,
330
, erbB-2 and response to doxorubicin in patients with
axillary lymph node-positive, hormone receptor-negative breast
cancer.
et al.
J Natl Cancer Inst
, 1998.
90
(18): 1361-1370.
112. Pritchard, K.I.,
, HER2 and responsiveness of breast cancer to
adjuvant chemotherapy.
et al.
N Engl J Med
, 2006.
354
(20): 2103-2111.
113. Thor, A.D.,
, erbB-2, p53, and efficacy of adjuvant therapy in lymph
node-positive breast cancer.
et al.
J Natl Cancer Inst
, 1998.
90
(18): 1346-
1360.
114. Levine, M.N.,
, Randomized trial of intensive cyclophosphamide,
epirubicin, and fluorouracil chemotherapy compared with
cyclophosphamide, methotrexate, and fluorouracil in premenopausal
women with node-positive breast cancer. National Cancer Institute of
Canada Clinical Trials Group.
et al.
J Clin Oncol
, 1998.
16
(8): 2651-2658.
115. Gennari, A.,
, HER2 status and efficacy of adjuvant anthracyclines
in early breast cancer: a pooled analysis of randomized trials.
et al.
J Natl
Cancer Inst
, 2008.
100
(1): 14-20.
116. Pegram, M.D.,
, The effect of HER-2/neu overexpression on
chemotherapeutic drug sensitivity in human breast and ovarian cancer
cells.
et al.
Oncogene
, 1997.
15
(5): 537-547.
117. Bieche, I.,
, Two distinct amplified regions at 17q11-q21 involved
in human primary breast cancer.
et al.
Cancer Res
, 1996.
56
(17): 3886-
3890.
118. Hoare, S.F.,
, Identification of genetic changes associated with drug
resistance by reverse
et al.
in situ
hybridization.
Br J Cancer
, 1997.
75
(2):
275-282.
119. Keith, W.N.,
, Co-amplification of erbB2, topoisomerase II alpha
and retinoic acid receptor alpha genes in breast cancer and allelic loss
et al.
